BioNTech is set to shutter multiple sites in Germany, impacting about 1,800 jobs, after efforts to find buyers fell through.

Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...

Eli Lilly’s portfolio of weight loss and diabetes medications have become a dominant force in the market—but access to the ...

INS is Gazyva’s second immune-mediated indication, following an approval last October in adult lupus nephritis, a potentially ...

The commercial environment facing today's life sciences sales teams looks very different from the one many organizations were ...

Bristol Myers Squibb plans another major round of job cuts in New Jersey, bringing the number of total layoffs the company ...

Merck & Co. has scored an FDA approval for its blockbuster-to-be Welireg to move into second-line treatment of kidney cancer, ...

From its original U.S. home base in Deerfield, Illinois, Lundbeck now plans to relocate its local headquarters to Greater ...

Par Health has issued a voluntary recall of two lots of the IV sedative dexmedetomidine HCl in 0.9% sodium chloride injection ...

In their lawsuit, BMS and Ono accuse Amgen of aiming to market its biosimilar ahead of the expiration of key U.S. patents ...

New phase 3 data show Vera Therapeutics’ Trutakna successfully stabilizes kidney function in IgA nephropathy patients, ...

Consumer drug behemoth Reckitt is dropping $600 million on a multi-year revamp of its U.S. operations. The health and hygiene ...